Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

The insulin-like growth factor (IGF) system plays an important role in a variety of physiologic processes and in diseases such as cancer. Although the role of the IGF system in cancer has been recognized many years ago, components of the system have only recently been targeted and shown to affect cell transformation, proliferation, survival, motility, and migration in tissue cultures and in mouse models of cancer. We have been hypothesizing that targeting IGF-II in addition to blocking its interaction with the IGF receptor type I (IGF-IR) would also allow to block that portion of the signal transduction through the insulin receptor that is due to its interaction with IGF-II. Lowering its level may also not induce up-regulation of its production as for IGF-I. Finally, targeting a diffusable ligand as IGF-II may not require penetration of the antibody inside tumors but could shift the equilibrium to IGF-II complexed with antibody so the ligand concentration would decrease in the tumor environment without the need for the antibody to penetrate the tumor. Here, we describe the identification and characterization of three novel anti-IGF-II fully human monoclonal antibodies. They bound with high (subnanomolar) affinity to IGF-II, did not cross-react with IGF-I and insulin, and potently inhibited signal transduction mediated by the IGF-IR interaction with IGF-II. The most potent neutralizer, IgG1 m610, inhibited phosphorylation of the IGF-IR and the insulin receptor, as well as phosphorylation of the downstream kinases Akt and mitogen-activated protein kinase with an IC50 of the order of 1 nmol/L at IGF-II concentration of 10 nmol/L. It also inhibited growth of the prostate cancer cell line DU145 and migration of the breast cancer line cells MCF-7. These results indicate an immunotherapeutic potential of IgG1 m610 likely in combination with other antibodies and anticancer drugs but only further experiments in mouse models of cancer and human clinical trials could evaluate this possibility. [Mol Cancer Ther 2006;5(1):114–20]

[1]  Yi Sun,et al.  Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. , 2002, Current cancer drug targets.

[2]  G Konecny,et al.  The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.

[3]  C. Osborne,et al.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. , 1989, Cancer research.

[4]  Adrian V. Lee,et al.  A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells* , 2004, Journal of Biological Chemistry.

[5]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[6]  D. Leroith.  Insulin-like growth factor receptors and binding proteins. , 1996, Bailliere's clinical endocrinology and metabolism.

[7]  R. Baserga.  The contradictions of the insulin-like growth factor 1 receptor , 2000, Oncogene.

[8]  D. Leroith,et al.  The new kid on the block(ade) of the IGF-1 receptor. , 2004, Cancer cell.

[9]  K. Shitara,et al.  Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors , 2004, Cancer Research.

[10]  Dennis R. Burton,et al.  Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody , 2022 .

[11]  D. Yee,et al.  Insulin-like growth factor-I and breast cancer therapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[13]  K. Shitara,et al.  Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers , 2005, Clinical Cancer Research.

[14]  W. R. Bishop,et al.  Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. , 2002, Molecular Cancer Therapeutics.

[15]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[16]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[17]  D. Yee,et al.  A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. , 2003, Cancer research.

[18]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[19]  D. Yee,et al.  The therapeutic potential of agents targeting the type I insulin-like growth factor receptor , 2004, Expert opinion on investigational drugs.

[20]  D. Leroith,et al.  The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. , 2005, Cytokine & growth factor reviews.

[21]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[22]  E. K. Maloney,et al.  An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. , 2003, Cancer research.